Forty Seven Inc. (FTSV)’s Financial Results Comparing With Global Cord Blood Corporation (NYSE:CO)

Forty Seven Inc. (NASDAQ:FTSV) and Global Cord Blood Corporation (NYSE:CO), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Forty Seven Inc. 9 0.00 24.99M -2.89 0.00
Global Cord Blood Corporation 5 0.72 27.63M 0.27 21.25

Table 1 highlights Forty Seven Inc. and Global Cord Blood Corporation’s gross revenue, earnings per share and valuation.

Profitability

Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Forty Seven Inc. 285,273,972.60% -105.1% -61.5%
Global Cord Blood Corporation 564,903,600.42% 0% 4.6%

Liquidity

Forty Seven Inc.’s Current Ratio and Quick Ratio are 8.1 and 8.1 respectively. The Current Ratio and Quick Ratio of its competitor Global Cord Blood Corporation are 8.6 and 8.6 respectively. Global Cord Blood Corporation therefore has a better chance of paying off short and long-term obligations compared to Forty Seven Inc.

Analyst Recommendations

Forty Seven Inc. and Global Cord Blood Corporation Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Forty Seven Inc. 0 0 1 3.00
Global Cord Blood Corporation 0 0 0 0.00

$18 is Forty Seven Inc.’s average price target while its potential upside is 27.93%.

Institutional & Insider Ownership

The shares of both Forty Seven Inc. and Global Cord Blood Corporation are owned by institutional investors at 54.7% and 18.2% respectively. Forty Seven Inc.’s share owned by insiders are 3.6%. On the other hand, insiders owned about 49.6% of Global Cord Blood Corporation’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Forty Seven Inc. -1.87% -16.04% -51.23% -38.96% -45.86% -43.38%
Global Cord Blood Corporation 0.35% 1.4% -13.6% -7.37% -26.46% -10.39%

For the past year Forty Seven Inc. was more bearish than Global Cord Blood Corporation.

Summary

On 10 of the 12 factors Global Cord Blood Corporation beats Forty Seven Inc.

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2018, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.